
|Articles|March 12, 2014
- Immunotherapy (Issue 2)
- Volume 2
- Issue 1
The Outlook for CAR-Modified T Cells
Author(s)Renier J. Brentjens, MD, PhD
Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the outlook for CAR-modified T cells.
Advertisement
Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the outlook for CAR-modified T cells.
Read more about CAR-modified T cells and other immunotherapies for B-cell malignancies > >
Articles in this issue
almost 12 years ago
B-Cell Malignancies Faring Well With Immunotherapiesalmost 12 years ago
Update on Immunotherapy and Targeted Combination Therapiesalmost 12 years ago
How Immunotherapies are Changing the Treatment of Melanomaalmost 12 years ago
Progress Made With PD-L1 as Predictive Biomarkeralmost 12 years ago
Oncolytic Viral Therapies About to Spreadalmost 12 years ago
The Future of Immunotherapy Treatments in Lung Canceralmost 12 years ago
Checking in on Checkpoint InhibitorsAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Real-World Pola-R-CHP vs R-CHOP Effectiveness in Older DLBCL Patients
5









































